Effect of Injectable and Oral Contraceptives on Serum Lipids
- 1 October 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 114 (4) , 786-794
- https://doi.org/10.1097/aog.0b013e3181b76bea
Abstract
OBJECTIVE: To estimate the effects of using depot medroxyprogesterone acetate (DMPA) or oral contraceptives (OCs) containing 20 micrograms ethinyl estradiol and 0.15 mg desogestrel on serum lipid levels. METHODS: Serum lipids were measured at baseline and every 6 months thereafter for 3 years in 703 white, African-American, and Hispanic women using DMPA, OC, or nonhormonal birth control. Those who discontinued DMPA were followed for up to 2 additional years. Participants completed questionnaires containing demographic and behavioral measures every 6 months and underwent 24-hour dietary recalls annually. Mixed-model regression analyses and general-estimating-equations procedures were used to estimate changes over time in lipids by method along with their predictors. RESULTS: Users of OCs experienced significantly greater increases in levels of triglycerides, total cholesterol, very-low-density lipoprotein (VLDL) cholesterol, and high-density lipoprotein (HDL) cholesterol than did nonhormonal-contraceptive users (P<.001). However, no difference was noted in the low-density lipoprotein (LDL) cholesterol:HDL ratio between OC users and nonhormonal-contraceptive users. Among DMPA users, HDL levels initially decreased for 6 months but then returned to baseline. The LDL:HDL ratio rose in the first 6 months of DMPA use but then dropped back to baseline over the next 24 months. After DMPA was discontinued, triglyceride, VLDL, and HDL levels were significantly higher in women who used OCs than in those who chose nonhormonal (P<.05) methods. CONCLUSION: Use of very-low-dose OCs containing desogestrel can elevate lipid levels. Users of DMPA were at increased risk of developing an abnormally low HDL level as well as an abnormally high LDL level and an increase in the LDL:HDL cholesterol ratio, although these effects appeared to be temporary. LEVEL OF EVIDENCE: IIThis publication has 39 references indexed in Scilit:
- Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive useAmerican Journal of Obstetrics and Gynecology, 2009
- Effects of Depot Medroxyprogesterone Acetate and 20-Microgram Oral Contraceptives on Bone Mineral DensityObstetrics & Gynecology, 2008
- Physiologic and psychologic symptoms associated with use of injectable contraception and 20 μg oral contraceptive pillsAmerican Journal of Obstetrics and Gynecology, 2008
- Long-Term Use of Contraceptive Depot Medroxyprogesterone Acetate in Young Women Impairs Arterial Endothelial Function Assessed by Cardiovascular Magnetic ResonanceCirculation, 2002
- Peak bone mass in young womenJournal of Bone and Mineral Research, 1995
- A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD usersContraception, 1993
- The New Era in Oral ContraceptionObstetrical & Gynecological Survey, 1992
- Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolismContraception, 1991
- Metabolic effects of depot-medroxyprogesterone acetate in long-term users: A cross-sectional studyInternational Journal of Gynecology & Obstetrics, 1986
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986